Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma
DOI:
https://doi.org/10.3889/oamjms.2022.8439Keywords:
Cancer stem cells, Aldehyde dehydrogenase 1A1, Triple negative breast cancerAbstract
Background: Increasing evidence has proposed that tumor contains tumor initiating cells or cancer stem cells (CSCs) are responsible for its progression and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1) has recently been identified as a marker for cancer stem cells in some human malignancies including breast cancer.Triple negative breast carcinomas (TNBCs) are group of primary breast tumors with aggressive clinical behavior that have no targeted therapy at present.
Aim: The assessment of immunohistochemical expression of ALDH1A1 in triple negative breast carcinoma and its correlation with the clinicopathological features of TNBC.
Material and Methods: This study consisted of 60 cases of TNBC. Immunohistochemical reactions were carried out by using ALDH1A1 monoclonal antibody. A total score of ALDH1A1 expression is obtained by multiplying the score of staining intensity & percentage of stained cells to obtain score ranging from 0 up to 300. Due to the relatively large number of positive cases, a statistical analysis
was performed with a negative (score ≤ 10) and positive (score > 10) cutoff [1].
Results: Evaluation of the results of immunostaining for ALDH1A1 showed 88.3% of totalcases (53 cases) having a positive cytoplasmic reactivity. Statistical analysis for a possible correlation between ALDH1A1 expression and prognostic clinicopathological parameters; age, size, tumor grade, histologic subtypes, lymphovascular invasion, intraductal components, tumor infiltrating lymphocytes and TNM stage grouping revealed a non-significant correlation.
Conclusion: ALDH1A1 couldn’t be used solely as a diagnostic or prognostic marker In TNBCs. Further research combining with other biomarkers and with a greater number of patients is necessary to confirm the role of ALDH1A1 in TNBC.
Key words: Cancer stem cells (CSCs), Aldehyde dehydrogenase 1A1 (ALDH1A1), Triple Negative Breast cancer (TNBC).
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ma F, Li H, Li Y, Ding X, Wang H, Fan Y, et al. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC). Medicine (Baltimore). 2017;96(14):e6561. https://doi.org/10.1097/MD.0000000000006561 PMid:28383433
Butti R, Gunasekaran VP, Kumar TV, Banerjee P, Kundu GC. Breast cancer stem cells: Biology and therapeutic implications. Int J Biochem Cell Biol. 2019;107:38-52. https://doi.org/10.1016/j.biocel.2018.12.001 PMid:30529656
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-90. https://doi.org/10.1038/nrclinonc.2016.66 PMid:27184417
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26-35. https://doi.org/10.1016/j.breast.2015.07.008 PMid:26253814
Pires BR, De Amorim IS, Souza LD, Rodrigues JA, Mencalha AL. Targeting cellular signaling pathways in breast cancer stem cells and its implication for cancer treatment. Anticancer Res. 2016;36(11):5681-91. https://doi.org/10.21873/anticanres.11151 PMid:27793889
Vassalli G. Aldehyde dehydrogenases: Not just markers, but functional regulators of stem cells. Stem Cells Int. 2019;2019;3904645. https://doi.org/10.1155/2019/3904645 PMid:30733805
Martinez-Cruzado L, Tornin J, Santos L, Rodriguez A, García- Castro J, Morís F, et al. Aldh1 expression and activity increase during tumor evolution in sarcoma cancer stem cell populations. Sci Rep. 2016;6:27878. https://doi.org/10.1038/srep27878 PMid:27292183
Yang W, Wang Y, Wang W, Chen Z, Bai G. Expression of aldehyde dehydrogenase 1A1 (ALDH1A1) as a prognostic biomarker in colorectal cancer using immunohistochemistry. Med Sci Monit. 2018;24:2864-72. https://doi.org/10.12659/MSM.910109 PMid:29748529
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181-5. https://doi.org/10.1111/his.14091 PMid:32056259
Mei F, Liu JY, Xue WC. Histopathological grading of invasive breast carcinoma: Nottingham histopathological grading system. Chin J Pathol. 2019;48(8):659-64.
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: Breast cancer. Ann Surg Oncol. 2018;25(7):1783-5. https://doi.org/10.1245/s10434-018-6486-6 PMid:29671136
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72. https://doi.org/10.5858/134.7.e48 PMid:20586616
Wolff AC, Hammond ME, Hayes DF. Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012;104(12):957-8. https://doi.org/10.1093/jnci/djs243 PMid:22581974
Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161(4):1223-33. https://doi.org/10.1016/S0002-9440(10)64399-4 PMid:12368196
Rakha E, El-Sayed M, Green A, Lee A, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007;109(1):25-32. https://doi.org/10.1002/cncr.22381 PMid:17146782
Rebecca D, Maureen T, Kathleen P, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-34. https://doi.org/10.1158/1078-0432.CCR-06-3045 PMid:17671126
Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23(1):123-33. https://doi.org/10.1038/modpathol.2009.145 PMid:19855377
Nassar A, Sookhan N, Santisteban M, Bryant SC, Boughey JC, Giorgadze T, et al. Diagnostic utility of snail in metaplastic breast carcinoma. Diagn Pathol. 2010;5:76. https://doi.org/10.1186/1746-1596-5-76 PMid:21110878
Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: A clinical study of triple-negative breast carcinomas. PLoS One. 2012;7(9):e45831. https://doi.org/10.1371/journal.pone.0045831 PMid:23049873
Hegmane A, Liepniece-Karele I. Response to neoadjuvant therapy and long-term outcome in patients with triple negative breast cancer. Eur Sci J. 2014;10(12):1857-7881.
Ishikawa Y, Horiguchi J, Toya H, Nakajima H, Hayashi M, Tagaya N, et al. Triple-negative breast cancer: Histological subtypes and immunohistochemical and clinicopathological features. Sci J. 2011;102(3):656-62. https://doi.org/10.1111/j.1349-7006.2011.01858
Disis ML and Stanton SE. Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm. Virginia, United States: ASCO Educational Book; 2015.
Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple negative breast cancer. Ann Oncol. Ann Oncol. 2016;27(2):249-56. https://doi.org/10.1093/annonc/mdv571 PMid:26598540
Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, et al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: Does the survival vary for all stages? World J Surg. 2016;40(6):1362-72. https://doi.org/10.1007/s00268-016-3422-4 PMid:26842691
Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, et al. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol. 2014;2(2):245-51. https://doi.org/10.3892/mco.2013.230 PMid:24649341
Atwa HA, Ibrahim HM, Ismail EI, Ibrahim IM. ALDH 1A1 and caveolin-1 expression in triple negative breast cancer. Oncol Transl Med. 2017;3:185-96. https://doi.org/10.1007/s10330-017-0231-1
Murrja E, Turna ZH, Ozturk MA, Cinkaya A, Ozturk T. Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer. Med Sci Discov. 2014;1(2):44. https://doi.org/10.17546/msd.82203
Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1-mark breast epithelium at risk for breast cancer development. Mod Pathol. 2011;24(6):786-93. https://doi.org/10.1038/modpathol.2011.8. PMid:21399615
Madjd Z, Ramezani B, Molanae S, Asadi-Lari M. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973-8. https://doi.org/10.7314/apjcp.2012.13.6.2973 PMid:22938492
Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, et al. Enriched CD44+/CD24-population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353(2):153-9. https://doi.org/10.1016/j.canlet.2014.06.022 PMid:25130168
Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, et al. Prognostic impact of ALDH1 in breast cancer: A story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010;123(1):97-108. https://doi.org/10.1007/s10549-009-0619-3 PMid:19911270
Hosni H, Daoud S, Bassam A. Immunohistochemical study of stem cell marker ALDH 1A1 and BRCA1 in breast cancer. Acad J Cancer Res 2014;7:1-7.
Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, et al. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers. 2013;28(4):e357-64. https://doi.org/10.5301/jbm.5000048 PMid:24338721
Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, et al. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology. 2011;59(4):776-80. https://doi.org/10.1111/j.1365-2559.2011.03884.x PMid:22014057
Kurbel S. In search of triple-negative DCIS: Tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol. 2013;34(1):1-7. https://doi.org/10.1007/s13277-012-0602-1 PMid:23208673
Khoury T, Ademuyiwa FO, Chandrasekhar R, Jabbour M, Deleo A, Ferrone S, et al. Aldehyde dehdrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol. 2012;25(3):388-97. https://doi.org/10.1038/modpathol.2011.172 PMid:22080062
Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: A systematic review and meta-analysis. BMC Cancer. 2014;14:444. https://doi.org/10.1186/1471-2407-14-444 PMid:24938375
Downloads
Published
How to Cite
License
Copyright (c) 2022 Marwa Abdel Nasser Mohamed, Badawia Bayoumi Ibrahim, Samar Abdel Monem El Sheikh, Mona Salah Abdel Magid (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
